良恶性腹水鉴别诊断的研究进展

孙娟; 牛春燕

doi:10.3969/j.issn.1001-5256.2016.07.051

良恶性腹水鉴别诊断的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.07.051

孙娟,
牛春燕

1. 西安医学院
2. 西安医学院第一附属医院消化内科

基金项目:

陕西省教育厅科研项目(12JK0756)；

详细信息

中图分类号: R442.5;R730.43
计量
- 文章访问数: 3015
- HTML全文浏览量: 19
- PDF下载量: 507
- 被引次数: 0
出版历程
- 出版日期: 2016-07-20

Research advances in differential diagnosis of benign and malignant ascites

Research funding:

摘要

摘要: 良恶性腹水的鉴别诊断对于明确病因、预后评价及治疗方案的确定均有重要价值。腹水的诊断方法很多,但至今尚无一种理想的方法能兼有高敏感度和特异度,同时满足临床经济学和可行性等要求。因此,寻找理想的腹水鉴别诊断方法已成为当前研究的重要课题。阐述了分子生物学检测、细胞学检查、肿瘤标志物联合检测、常规检测等诊断方法在良恶性腹水鉴别诊断中的临床应用价值,分析了相关生物学标志物的诊断效能,认为多指标联合检测可提高对良恶性腹水的鉴别诊断价值。
- 腹水 /
- 诊断,鉴别 /
- 综述
Abstract: Differential diagnosis of benign and malignant ascites is of a great value in determining etiology,evaluating prognosis,and determining therapy regimens. There are many diagnostic methods for ascites,but up to now,no method can achieve high sensitivity and specificity and meet the requirements of clinical economics and feasibility at the same time. Therefore,searching for an ideal method for differential diagnosis of ascites has become an important topic of current research. This article describes the clinical value of diagnostic methods,such as molecular biological detection,cytological examination,combined determination of tumor markers,and routine tests,in the differential diagnosis of benign and malignant ascites,analyzes the diagnostic efficiency of related biomarkers,and points out that combined determination of various parameters has an increased value in the differential diagnosis of benign and malignant ascites.
- ascites /
- diagnosis /
- differential

HTML全文

参考文献(51)

[1]LI X,HE M,ZOU B.Value of miRNA-26a level in benign or malignant ascites[J].China Med Herald,2014,23(11):51-53,75.(in Chinese)李曦,何敏,邹兵.miRNA-26a在良、恶性腹水鉴别诊断中的意义[J].中国医药导报,2014,23(11):51-53,75.

[2] AKINCILAR SC,UNAL B,TERGAONKAR V.Reactivation of telomerase in cancer[J].Cell Mol Life Sci,2016,73(8):1659-1670.

[3]ZHANG Y,TOH L,LAU P,et al.Human telomerase reverse transcriptase(h TERT)is a novel target of the Wnt/β-catenin pathway in human cancer[J].J Biol Chem,2012,287(39):32494-32511.

[4]WANG JD,MA J,WANG FY,et al.Amplification of the telomeraes RNA component gene a new genetic marker for disease progression and prognosis in esophageal squamous cell carcinoma[J].Dis Esophagus,2013,26(7):737-745.

[5]WELLENHOFER A,BRUSTMANN H.Expression of human telomerase reverse transcriptase in vulvar intraepithelial neoplasia and squamous cell carcinoma:an immunohistochemical study with survivin and p53[J].Arch Pathol Lab Med,2012,136(11):1359-1365.

[6]MOCELIN S,POOLEY KA,NITTI D,et al.Telomerase and the search for the end of cancer[J].Trends Mol Med,2013,19(2):125-133.

[7]BERNARDES de JESUS B,BLASCO MA.Telomerase at the intersection of cancer and aging[J].Trends Genet,2013,29(9):513-520.

[8]PARK ES,LEE J,KANG SY,et al.A comparative study of telomerase activity and cytologic diagnosis in malignant ascites[J].Ana Quant Cytopathol Histpathol,2013,35(3):146-151.

[9]CAO M,YIE SM,LIU J,et al.Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal,gastric,esophagea and lung cancer[J].Tissue Antigens,2011,78(2):120-128.

[10]PARK GM,LEE S,PARK B,et al.Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis[J].Biochem Biophys Res Commun,2004,313(3):606-611.

[11]YAN WH.HLA-G expression in cancers:potential role in diagnosis,prognosis and therpy[J].Endocr Metab Immune Disord Drug Targets,2011,11(1):76-89.

[12]YAN WH.Human leukocyte antigen-G in cancer:are they clinically relevant?[J].Cancer Lett,2011,311(2):123-130.

[13]YIE SM,HU Z.Human leukocyte antigen-G(HLA-G)as a marker for diagnosis,prognosis and tumor immue escape in human malignancies[J].Histol Histopathol,2011,26(3):409-420.

[14]OTROCK ZK,MAKAREM JA,SHAMSEDDINE AI,et al.Vascular endothelial growth factor family of ligands and receptors:review[J].Blood Cells Mol Dis,2007,38(3):258-268.

[15]COSMAI L,GALLIENI M,LIGUIGLI W,et al.Renal toxicity of anticancer agents targeting vascular endothelial growth factor(VEGF)and its receptors(VEGFRs)[J].J Nephrol,2016.[Epub ahead of print]

[16]KERAMOCHI H,HAYASHI K,UCHIDA K,et al.Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer[J].Clin Cancer Res,2006,12(1):29-33.

[17]ZHAN N,DONG WG,WANG J.The clinical significance of vascular endothelial growth factor in malignant ascites[J].Tumour Biol,2016,37(3):3719-3725.

[18]LYU XG,DONG WG,ZHAN N,et al.Diagnostic value of vascular endothelial growth factor in differentiation of malignant ascites:a meta-analysis[J].Chin J Evid-Based Med,2011,11(2):220-225.(in Chinese)吕晓光,董卫国,詹娜,等.血管内皮生长因子对恶性腹腔积液诊断价值的meta分析[J].中国循证医学杂志,2011,11(2):220-225.

[19]WEI H,QIN S,YIN X,et al.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites[J].Oncol Lett,2015,9(6):2694-2700.

[20]NOH S,JUNG JJ,JUNG M,et al.Body fluid MMP-2 as a putative biomarker in metastatic breast cancer[J].Oncol Lett,2012,3(3):699-703.

[21]NOH S,JUNG JJ,JUNG M,et al.MMP-2 as a putative biomarker for carcinomatosis in gastric cancer[J].Hepatogastroenterology,2011,58(112):2015-2019.

[22]NESI G,BRUNO L,SAIEVA C,et al.DNA ploidy and S-phase fraction as prognostic factors in surgically resected gastric carcinoma:a 7-year prospective study[J].Anticancer Res,2007,27(6C):4435-4441.

[23]ZHANG L,WANG Q,LI F,et al.Meta-analysis on the diagnostic value of DNA aneuploid for malignant ascites[J].Shandong Med J,2010,50(43):37-39.(in Chinese)张垒,王强,李富,等.DNA异倍体检测对恶性腹水诊断价值的Meta分析[J].山东医药,2010,50(43):37-39.

[24] GILL M,SINGH U,MAHAATRA QS,et al.Role of argyrophilic nucleolar organizer region staining in identification of malignant cells in effusion[J].J Cytol,2011,28(4):191-195.

[25]ROCHER AE,GUERRA F,ROFRANO J,et al.Sensitivity and specificity of cytodiagnosis of body fluids in a laboratory of urgencies[J].Biotech Histochem,2011,86(5):326-332.

[26]ZHU FL,LING AS,WEI Q,et al.Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites[J].Asian Pac J Cancer Prev,2015,16(2):719-722.

[27]LIU F,KONG XJ,DOU Q,et al.Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites[J].Ann Hepatol,2014,13(3):357-363.

[28] PAVITHRA V,SATHISHA TG,KASTURI K,et al.Serum levels of metal ions in femal patients with breast cancer[J].J Clin Diagn Res,2015,9(1):25-27.

[29] KABA M,PIRINCCI N,YUKSEL MB,et al.Serum levels of trace elements in patients with prostate cancer[J].Asian Pac J Cancer Prev,2014,15(6):2625-2629.

[30]SHETTY SR,BABU S,KUMARI S,et al.Status of trace elements in saliva of oral precancer and oral cancer patients[J].J Cancer Res Ther,2015,11(1):146-149.

[31]CHEN H,TAN C,WU T.Ensemble modeling coupled with six element concentrations in human blood for cancer diagnosis[J].Biol Trace Elem Res,2011,143(1):143-152

[32]KIM ES,LIM CS,CHUN HJ,et al.Detection of Cu(Ⅰ)and Zn(Ⅱ)ions in colon neoplasm[J].J Clin Pathol,2012,65(10):882-887.

[33]DING R,JIA JD.Progress in evaluation and treatment of hepatic iron overload[J].J Clin Hepatol,2014,30(9):961-964.(in Chinese)丁蕊,贾继东.肝脏铁过载的评估及治疗新进展[J].临床肝胆病杂志,2014,30(9):961-964.

[34] UCHINO K,TATEISHI R,FUJIWARA N,et al.Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients[J].Hepatol Res,2016,46(4):259-268.

[35]JI M,LI XD,SHI HB,et al.Clinical significance of serum ferritin in elderly patients with primary lung carcinoma[J].Tumour Biol,2014,35(10):10195-10199.

[36] CHEKHUN SV,LUKYANOVA NY,SHVETS YV,et al.Significance of ferritin expression in formation of malignant phenotype of human breast cancer cells[J].Exp Oncol,2014,36(3):179-183.

[37]KUCUKGOZ GULEC U,PAYDAS S,GUZEL AB,et al.Comparative analysis of CA-125,ferritin,beta-2 microglobulin,lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia[J].Med Oncol,2012,29(4):2937-2943.

[38]ALKHATEEB A,ZUBRITSKY L,KINSMAN B,et al.Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease[J].J Gastrointest Cancer,2014,45(2):161-167.

[39]WU J,WANG HL.Clinical significance of tumor markers of tumor ferritin,CA125 combined detection in benign and malignant ascites’s differential diagnosis[J].China J Modern Med,2014,24(36):35-38.(in Chinese)吴江,汪宏良.铁蛋白与CA125联合检测在良、恶性腹水鉴别诊断中的临床意义[J].中国现代医学杂志,2014,24(36):35-38.

[40]YUAN K,KUCIK D,SINGH RK,et al.Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties[J].Int JOncol,2008,32(4):797-807.

[41]MOSSAD NA,MAHMOUD EH,OSMAN EA,et al.Evaluation of squamous cell carcinoma natigen-immunoglobulin M complex(SC-CA-IGM)and alpha-L-fucosidase(AFU)as novel diagnostic biomarkers for hepatocellular carcinoma[J].Tumor Biol,2014,35(11):11559-11564.

[42]FAWZY MONTASER M,AMIN SAKR M,OMAR KHALIFA M.Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma[J].Arab J Gastroenterol,2012,13(1):9-13.

[43]WANG K,GUO W,LI N,et al.Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following he patectomy:a large-scale,long-term study[J].Br J Cancer,2014,110(7):1811-1819.

[44]SU SB,QIN SY,GUO XY,et al.Assessment by meta-analysis of interferon-gamma for the diagnosis of tuberculous peritonitis[J].World J Gastroenterol,2013,19(10):1645-1651.

[45]TAO L,NING HJ,NIE HM,et al.Diagnostic value of adenosine deaminase in ascites for tuberculosis ascites:a meta-analysis[J].Diagn Microbiol Infect Dis,2014,79(1):102-107.

[46]WALIA A,YANG JF,HUANG YH,et al.Endostatin’s emerging roles in angiogenesis,lymphangiogenesis,disease,and clinical applications[J].Biochim Biophys Acta,2015,1850(12):2422-2438.

[47]CHENG D,LIANG B,KONG H,et al.Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites[J].Med Oncol,2012,29(2):1397-1402.

[48] WEI H,QIN S,YIN X,et al.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites[J].Oncol Lett,2015,9(6):2694-2700.

[49]WU CY,WANG W,CHEN X,et al.Efficacy of recombinant human endostatin in treatment of malignant peritoneal effusion in mice and its mechanisms of action[J].Chin J Clin Pharmacol Ther,2014,19(5):507-511.(in Chinese)吴春艳,王伟,陈鑫,等.重组人血管内皮抑素治疗小鼠恶性腹腔积液疗效及作用机制研究[J].中国临床药理学与治疗学,2014,19(5):507-511.

[50]PEDRAZZANI C,CARUSO S,CORSO G,et al.Influence of age on soluble E-cadherin serum levels prevents its utility as a disease marker in gastric cancer patients[J].Stand J Gastroenterol,2008,43(6):765-766.

[51]MOGHADDAM NA,TAHRIRIAN R,EFTEKHARI M,et al.Diagnostic value of E-cadherin and fibronectin in differentiation between reactive mesothelial and adenocarcinoma cells in serous effusions[J].Adv Biomed Res,2012,1:56

施引文献

资源附件(0)

访问统计